Brzozowska, M
Disclaimer: The information provided on this website is intended for educational purposes only and is not intended as advice on usage, dosage, or administration
Further investigation of Luteolin could demonstrate it is beneficial as an anti-anaphylactic compound
You understand and accept that there are inherent risks involved in shipping refrigerated products which may affect the efficacy of this product
Seek medical advice within 2448 hours if: Nausea persists without improvement despite management strategies Symptoms significantly worsen rather than improve over time Nausea is accompanied by persistent vomiting (more than 24 hours) that prevents adequate fluid or medication intake Signs of dehydration develop: dark urine, dizziness, reduced urination, dry mouth, or confusion Significant unintentional weight loss occurs (beyond expected therapeutic effect) Nausea interferes substantially with daily activities, work, or quality of life Recurrent hypoglycaemia occurs, particularly if taking Ozempic alongside insulin or sulfonylureas (medication review may be needed) Seek urgent medical attention (same day GP, NHS 111, or A&E) if: Severe, persistent abdominal pain , particularly in the upper abdomen, which may indicate pancreatitis (a rare but serious side effect of GLP-1 agonists) [1] [2] Vomiting with severe abdominal pain that radiates to the back Signs of severe dehydration or inability to keep down any fluids Right upper quadrant pain, fever, or yellowing of skin/eyes , which may indicate gallbladder problems (GLP-1 receptor agonists can increase the risk of gallstone formation) [1] [2] Reduced urine output, swelling, or breathlessness which may indicate acute kidney injury from dehydration Allergic reaction symptoms : facial swelling, difficulty breathing, or widespread rash The MHRA's Yellow Card scheme (yellowcard.mhra.gov.uk) allows patients and healthcare professionals to report suspected side effects directly, contributing to ongoing medication safety monitoring
It is also administered via subcutaneous injection, typically once a week
